Skip to main content

Advertisement

Table 1 General data of the 31 AAV patients in active stage

From: Platelets are activated in ANCA-associated vasculitis via thrombin-PARs pathway and can activate the alternative complement pathway

Parameters Value
General clinical data
 No. subjects 31
 Gender (M/F) 19/12
 Age 59.4 ± 13.2
 ANCA target antigen (MPO/PR3) 29/3
 Initial Scr (μmol/L) 448.6 ± 250.6
 Urinary protein (g/24 hr) 0.76 (00.5–2.01)
 BVAS 18.3 ± 5.7
 Renal involvement 21 (91.3%)
 Pulmonary involvement 21 (91.3%)
 ENT involvement 6 (26.1%)
 Nervous system involvement 5 (21.7%)
Pathologic data
 No. subjects 20
 Glomerular lesions
  Total crescents 58% (36–77%)
  Cellular crescents 42% (26–57%)
 Tubulointerstitial lesions
  Interstitial infiltration(−/+/++/+++) 0/6/14/0
  Interstitial fibrosis(−/+/++) 1/6/13
  Tubular atrophy(−/+/++) 2/13/5
Treatment data
 Prednisone 31
 Methylprednisolone pulse 17
 Plasma exchange 15
 CTX (intravenous/oral) 28/3
  1. Abbreviations: AAV antineutrophil cytoplasmic antibody-associated vasculitis, ANCA antineutrophil cytoplasmic antibody, MPO myeloperoxidase, PR3 protinase 3, Scr serum creatinine, BVAS Birmingham Vasculitis Activity Score, ENT ear, nose and throat, CTX cyclophosphamide